The Dutch bispecific antibody developer Merus BV has appointed Mark Iwicki as president of its supervisory board. He will replace Gerard van Odijk who has held the position for the past seven years. Mr Iwicki was most recently president and chief executive officer of Civitas Therapeutics Inc until it was acquired by Acorda Therapeutics Inc in 2014. He has also been the CEO of Blend Therapeutics In and of Sunovion Pharmaceuticals Inc.
Merus announced the appointment on 1 June 2015.
Copyright 2015 Evernow Publishing Ltd